- Raised $33M funding round, Mar 2022
- Raised $14M funding round led by M Ventures, Apr 2024
- Raised $8.5M funding round led by Debiopharm Group, Jul 2020
About
Nucleai’s technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, translating them into actionable insights that can accelerate the development of life-saving treatments and diagnostics.
The company deploys an AI spatial tool for patient selection in a clinical trial, in partnership with a top 10 biopharma company. The platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, and multiplex immunofluorescence), conducts advanced spatial analysis, and delivers actionable insights. These insights empower pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of next-generation treatments such as bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy.
Nucleai is working with more than 60 percent of the Top 20 biopharma companies in the world, and has an ecosystem of partners across diagnostics, contract research organizations (CROs), and life sciences tools companies.
Funding history · 4 rounds · $60.5M total
Q&A
- What is Nucleai's primary focus?
- Nucleai specializes in a Spatial Biology Software Platform for Precision Medicine, leveraging intelligence-grade geospatial AI to analyze cellular interactions in patient biopsies.
- When was Nucleai founded?
- Nucleai was founded in July 2017.
- What is Nucleai's total funding to date?
- Nucleai has raised a total of $60,500,000 USD.
- When did Nucleai complete its most recent funding round and who were the lead investors?
- In April 2024, Nucleai completed a funding round of $14,000,000 USD, with M Ventures as a lead investor.
- Which investors participated in Nucleai's March 2022 funding round?
- The March 2022 funding round included Sanofi Ventures.
- What kind of partnerships does Nucleai engage in?
- Nucleai works with over 60 percent of the Top 20 biopharma companies globally and has an ecosystem of partners across diagnostics, contract research organizations (CROs), and life sciences tools companies.
- Where are Nucleai's headquarters located?
- Nucleai's headquarters are located in Tel Aviv-Yafo, Israel.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nucleai.ai/ |
|---|---|
| linkedin.com/company/25166605 | |
| YouTube | youtube.com/channel/UCDs2VIzHSJZ5ehWsG6bqcAw |
Identifiers & details
| Former names | nuclai |
|---|---|
| Founded | 2017-7 |
| Employees (exact) | 76 |
| Offices | Chicago |
Radar intelligence
Patents
| EPO | 22 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | nucleai.ai |
|---|